Overview
- A Justice Department final rule now places FDA‑approved and state‑licensed medical cannabis products in Schedule III under the Controlled Substances Act.
- The move does not legalize marijuana, leaves recreational and synthetic products outside the change, and allows states to keep prohibitions in place.
- DEA‑registered scientists will be able to obtain state‑market flower and manufactured products from DEA‑registered, state‑licensed businesses, opening the door to randomized clinical trials that were hard to run under Schedule I rules.
- Industry analysts say qualifying medical operators could gain access to banking, import and export permits, and relief from the IRS 280E tax rule once Treasury, IRS, and DEA clarify procedures.
- Next steps include a DEA public hearing in late June and interagency guidance, while researchers and clinicians caution that rescheduling is not a blanket safety signal, especially for adolescents, pregnant people, and those with cardiac or mental health risks.